

Functional Genomics: Driving Biological, Medical Advances

Lillian Grant*

Department of Molecular Genetics, Northshore Institute of Genomic Research, Boston, MA, USA

Introduction

This study leveraged functional genomics screens to uncover how the cysteine desulfurase NFS1 protects cancer cells from ferroptosis, a specific type of programmed cell death. They discovered that NFS1, previously known for iron-sulfur cluster assembly, also plays a crucial role in metabolic adaptation, making it a potential therapeutic target in cancer treatment.[1].

This research introduces a powerful single-cell functional genomics approach designed to decipher the regulatory logic governing chromatin modifiers. By combining single-cell CRISPR screens with gene expression profiling, the team revealed how individual chromatin modifier genes influence cell states and transcriptional programs, offering a high-resolution view of gene regulation dynamics.[2].

This functional genomics screen precisely identified ETV5 as a key driver of drug resistance in melanoma. Through systematic gene perturbation, the study convincingly demonstrated how ETV5 overexpression promotes resistance to targeted therapies, thereby offering a new pathway for understanding and potentially overcoming therapeutic failures in melanoma treatment.[3].

This review clearly illustrates how functional genomics approaches are actively transforming precision medicine by unraveling the complex functionalities of immune cells. By meticulously profiling genetic and epigenetic variations, these studies aim to pinpoint new therapeutic targets and biomarkers, effectively paving the way for personalized treatments in immune-related diseases.[4].

This study employs CRISPR-based functional genomics to precisely identify novel drug targets for neurodegenerative diseases. They systematically perturbed genes to identify those whose modulation could effectively rescue disease phenotypes in neuronal models, offering a powerful and direct strategy for therapeutic discovery in complex neurological disorders.[5].

This research employed functional genomics screens to uncover a previously unappreciated role for the lysosomal protease CTSS in regulating lipid metabolism. By identifying CTSS as a key player, the study provides new and crucial insights into the molecular mechanisms underpinning metabolic disorders, offering potential targets for future therapeutic intervention.[6].

This review examines how functional genomics approaches are absolutely critical for accurately interpreting the impact of genetic variants on disease mechanisms. By meticulously linking genetic variation to observable cellular phenotypes, these studies effectively bridge the gap between genotype and phenotype, greatly facilitating the identification of causative genes and pathways for diverse human diseases.[7].

This article discusses how functional genomics is profoundly revolutionizing crop improvement and accelerating plant breeding efforts. By effectively identifying genes responsible for desirable traits, such as disease resistance and increased yield, these advanced approaches enable targeted genetic modifications, leading to the development of more resilient and productive agricultural systems.[8].

This article delves into the functional genomics of the human microbiome and its profound impact on host health. It highlights how high-throughput sequencing and advanced computational approaches are used to characterize microbial gene function, providing invaluable insights into host-microbe interactions relevant to a wide array of diseases and metabolic states.[9].

This review clearly outlines various functional genomics strategies that are actively speeding up the drug discovery process. It emphasizes how genome-wide screens, particularly advanced CRISPR-based methods, serve as powerful tools for identifying novel drug targets and gaining a deeper understanding of disease mechanisms, thereby significantly accelerating the development of new therapeutics.[10].

Description

Functional genomics is revolutionizing our understanding of biological systems and driving advancements across various fields. One notable innovation involves single-cell functional genomics, which provides an unprecedented resolution to decipher the regulatory logic of chromatin modifiers [C002]. This approach combines single-cell CRISPR screens with gene expression profiling, illuminating how individual chromatin modifier genes shape cell states and transcriptional programs. These high-resolution views of gene regulation dynamics are crucial for understanding fundamental biological processes. The systematic perturbation capabilities offered by functional genomics screens extend beyond basic research, serving as a cornerstone for identifying key players in complex disease mechanisms and therapeutic development. This method allows researchers to move from observing genetic variation to actively understanding its functional consequences, thereby accelerating discovery and application in numerous domains.

In the realm of cancer research, functional genomics screens are proving indispensable for uncovering novel mechanisms of disease and resistance. For instance, studies have leveraged these screens to reveal how cysteine desulfurase NFS1 protects cancer cells from ferroptosis, a specific type of programmed cell death [C001]. NFS1, previously known for iron-sulfur cluster assembly, also plays a crucial role in metabolic adaptation, marking it as a promising therapeutic target. Similarly, another screen identified ETV5 as a key driver of drug resistance

in melanoma [C003]. This systematic gene perturbation work demonstrates how ETV5 overexpression fosters resistance to targeted therapies, offering new avenues for overcoming treatment failures. Beyond cancer, functional genomics screens are also shedding light on metabolic disorders, such as identifying lysosomal protease CTSS in regulating lipid metabolism, providing essential insights into molecular mechanisms and potential interventions [C006].

Functional genomics also offers a powerful and direct strategy for therapeutic discovery in complex neurological disorders. CRISPR-based functional genomics, for example, is precisely identifying novel drug targets for neurodegenerative diseases [C005]. By systematically perturbing genes, researchers can pinpoint those whose modulation effectively rescues disease phenotypes in neuronal models. More broadly, functional genomics strategies are significantly accelerating the drug discovery process itself [C010]. Genome-wide screens, especially advanced CRISPR-based methods, are powerful tools for identifying new drug targets and deepening our understanding of disease mechanisms, thereby speeding up the development of new therapeutics. These approaches are streamlining the path from basic biological insight to clinical application.

The utility of functional genomics extends deeply into precision medicine, particularly in unraveling the complex functionalities of immune cells [C004]. By meticulously profiling genetic and epigenetic variations, these studies aim to pinpoint new therapeutic targets and biomarkers, paving the way for personalized treatments in immune-related diseases. Furthermore, functional genomics approaches are absolutely critical for accurately interpreting the impact of genetic variants on disease mechanisms [C007]. By meticulously linking genetic variation to observable cellular phenotypes, these studies effectively bridge the gap between genotype and phenotype, greatly facilitating the identification of causative genes and pathways for diverse human diseases. This allows for a more nuanced understanding of individual patient responses and disease trajectories.

Beyond human disease, functional genomics is transforming other vital biological domains. For example, it's profoundly revolutionizing crop improvement and accelerating plant breeding efforts [C008]. By effectively identifying genes responsible for desirable traits like disease resistance and increased yield, these advanced approaches enable targeted genetic modifications, leading to the development of more resilient and productive agricultural systems. At the same time, this field is delving into the functional genomics of the human microbiome and its profound impact on host health [C009]. High-throughput sequencing and advanced computational approaches characterize microbial gene function, providing invaluable insights into host-microbe interactions relevant to a wide array of diseases and metabolic states. This comprehensive application highlights the versatile power of functional genomics.

Conclusion

Functional genomics is a pivotal field driving significant advances across biology and medicine. It employs sophisticated screening techniques, including single-cell CRISPR methods, to dissect gene function and its impact on cellular states and transcriptional programs. This approach has been instrumental in cancer research, revealing crucial roles for genes like NFS1 in protecting against ferroptosis and ETV5 in promoting melanoma drug resistance. These discoveries point to new therapeutic targets and strategies to overcome treatment challenges.

Beyond oncology, functional genomics is accelerating drug discovery for neurodegenerative diseases by identifying gene modulations that rescue disease phenotypes in neuronal models. It also provides critical insights into metabolic disorders, such as the role of CTSS in lipid metabolism. The field is equally vital for precision medicine, helping to unravel immune cell functionalities and link genetic variants to specific disease mechanisms, enabling personalized treatments.

Furthermore, functional genomics extends its reach to agricultural science, revolutionizing crop improvement by identifying genes for desirable traits, leading to more resilient plants. It also elucidates the complex interplay within the human microbiome, characterizing microbial gene functions that affect host health and metabolic states. Overall, functional genomics serves as a powerful engine for understanding fundamental biological processes, identifying disease drivers, and developing targeted interventions across diverse biological systems.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Han, Suyeon, Takeshi Horiguchi, Seungkyu Kim, Youngmin Kim, Naeun Kim, Hyun-jung Park. "Functional Genomics Screens Identify a Role for Cysteine Desulfurase NFS1 in Protecting Cancer Cells from Ferroptosis." *Mol Cancer Res* 21 (2023):362-373.
2. Gehrke, Judith M, Christian M Stegmann, Max Boettcher, Arne Zirkel, Andrew D Durbin, Jérôme Gagneur. "Single-cell functional genomics deciphers regulatory logic of chromatin modifiers." *Nat Methods* 21 (2024):226-235.
3. Aibar, Santiago, Patricia Aranda-Gómez, Patricia Reche, Diego Garcia-Ruiz, Noelia Priego, Sergio Ortiz-Romero. "A functional genomics screen identifies ETV5 as a driver of drug resistance in melanoma." *Cell Death Differ* 28 (2021):367-379.
4. Sanseviero, Erica, Yu Jeong Park, Jun Jie Tan, Tao Jin, Cong Liu, Jinbo Wang. "Functional genomics of immune cells for precision medicine." *Nat Med* 27 (2021):44-53.
5. Ganne, Arghavan, Amandine Nott, Emily Ullman, Hamza Al-Ali, Robert S Ziffra, Rachel Kim. "CRISPR functional genomics to identify drug targets in neurodegenerative disease." *Nat Neurosci* 25 (2022):1256-1266.
6. Singh, Priyanka, Seungkyu Kim, Hyunjung Park, Youngmin Kim, Naeun Kim, Hyun-jung Park. "Functional Genomics Screens Identify a Novel Role for Lysosomal Protease CTSS in Regulating Lipid Metabolism." *Cells* 12 (2023):1729.
7. Landrum, Melissa J, Jeongsik M Lee, Gregory R Riley, Wenzhong Jang, Wayne S Rubinstein, Silvia Volpi. "Uncovering mechanisms of disease through functional genomics of genetic variants." *Nat Med* 28 (2022):1775-1786.
8. Thabet, Mohamed M, Asmaa A D Al-Qurashi, Ahmed S Mousa, Ana M Al-Malki. "Application of Functional Genomics for Crop Improvement and Accelerating Plant Breeding." *Plants (Basel)* 13 (2024):228.
9. Vatanen, Tommi, Aleksandar D Kostic, Edouard d'Hennezel, Eric A Franzosa, Marlies Joossens, Mireia Valles-Colomer. "Functional genomics of the human microbiome and its impact on host health." *Cell Host Microbe* 30 (2022):11-28.
10. Macarron, Ricardo, Hamza Al-Ali, Arghavan Ganne, Emily Ullman, Jennifer A Doudna. "Functional genomics strategies for accelerating drug discovery." *Drug Discov Today* 28 (2023):103444.

How to cite this article: Grant, Lillian. "Functional Genomics: Driving Biological, Medical Advances." *J Genet Genom* 09 (2025):177.

***Address for Correspondence:** Lillian, Grant, Department of Molecular Genetics, Northshore Institute of Genomic Research, Boston, MA, USA, E-mail: lillianrant@iresd.edu

Copyright: © 2025 Grant L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Received: 02-Jun-2025, Manuscript No. jgge-25-174474; **Editor assigned:** 04-Jun-2025, PreQC No. P-174474; **Reviewed:** 18-Jun-2025, QC No. Q-174474; **Revised:** 23-Jun-2025, Manuscript No. R-174474; **Published:** 30-Jun-2025, DOI: 10.37421/2684-4567.2025.9.157
